生态环境部发文—— 确保制药行业环评工作“放得活，管得好”

Core Viewpoint - The release of the "Opinions on Optimizing Environmental Impact Assessment (EIA) Work for Pharmaceutical Industry Construction Projects" aims to enhance the environmental management of the pharmaceutical sector while promoting green development [1][2] Group 1: Objectives of the Opinions - The Opinions are designed to optimize the EIA process for pharmaceutical projects, particularly when changes occur post-completion, ensuring a balance between flexibility and effective management [1] - The pharmaceutical industry is recognized as a strategic sector crucial for national economy and security, characterized by high R&D demands and rapid innovation [1] Group 2: EIA Management Improvements - The Opinions clarify that changes during the operational phase of projects do not require a new EIA, streamlining the process for companies [1] - It encourages the bundling of EIA documents for similar projects within the same industrial park, which enhances management efficiency and reduces the burden on enterprises [1] Group 3: Pollution Control Measures - The Opinions impose strict requirements for environmental risk prevention related to new pollutants and various pollution control measures for air, water, soil, and solid waste [2] - Specific measures include the management of hazardous substances like dichloromethane and trichloromethane, and the treatment of antibiotic dust emissions and wastewater containing active pharmaceutical ingredients [2] - Local ecological environment departments are tasked with strengthening implementation and supervision during and after the project [2]